We are live on ! Find out more
TPTX

Turning Point Therapeutics, Inc. Common Stock
TPTX

Delisted

TPTX was delisted on the 16th of August, 2022.

Back to rankings

Fund managers haven’t disclosed any holdings of TPTX yet.

TPTX Hedge Fund Activity: Q3 2022 in Review

0 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2022, worth a combined $0 — down 100% from $3.06B a quarter earlier.

Sellers outnumbered buyers: 208 funds closed out of TPTX and 0 opened new positions — a net loss of 208 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $313M sold.

  • 0 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2022, down from 208 in Q2 2022.
  • Funds reported $0 of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2022 and 208 closed out, a net change of -208 holders.
  • The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $313M sold.

Based on aggregated 13F filings for Q3 2022.